Allergic Rhinitis Market Research Report - Forecast till 2027

Allergic Rhinitis Market: Information by Type (Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Occupational Allergic Rhinitis), Treatment (Antihistamines, Corticosteroids, Immunotherapy, Decongestants and others), Route of Administration (Oral, Nasal and others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Stores) - Forecast till 2027

ID: MRFR/Pharma/1018-CR | February 2021 | Region: Global | 129 Pages         

1 Executive Summary

1.1 MARKET SYNOPSIS 14

1.2 KEY CONTRIBUTING FACTORS 15

2 Market Introduction

2.1 DEFINITION 16

2.2 SCOPE OF THE STUDY 16

2.3 RESEARCH OBJECTIVE 16

2.4 MARKET STRUCTURE 17

2.5 ASSUMPTIONS & LIMITATIONS 17

3 RESEARCH METHODOLOGY

3.1 DATA MINING 18

3.2 SECONDARY RESEARCH 19

3.3 PRIMARY RESEARCH 20

3.3.1 BREAKDOWN OF PRIMARY RESPONDENTS 21

3.4 FORECASTING TECHNIQUES 22

3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 23

3.5.1 BOTTOM-UP APPROACH 24

3.5.2 TOP-DOWN APPROACH 24

3.5.3 DATA TRIANGULATION 25

3.5.4 VALIDATION 25

4 MARKET DYNAMICS

4.1 INTRODUCTION 26

4.2 DRIVERS 27

4.2.1 RISING PREVALENCE OF ALLERGIC RHINITIS 27

4.2.2 GOVERNMENT INITIATIVES TO CREATE AWARENESS 27

4.2.3 INCREASING HEALTHCARE EXPENDITURE 27

4.3 RESTRAINTS 28

4.3.1 PATENT EXPIRY 28

4.3.2 SIDE EFFECTS OF TREATMENT FOR ALLERGIC RHINITIS 28

4.4 OPPORTUNITIES 28

4.4.1 INCREASING DEMAND IN DEVELOPING COUNTRIES 28

4.4.2 MORE ADVANCED PRODUCTS 28

5 MARKET FACTOR ANALYSIS

5.1 PORTER’S FIVE FORCES MODEL 29

5.1.1 BARGAINING POWER OF SUPPLIERS 30

5.1.2 BARGAINING POWER OF BUYERS 30

5.1.3 THREAT OF NEW ENTRANTS 30

5.1.4 THREAT OF SUBSTITUTES 30

5.1.5 INTENSITY OF RIVALRY 30

5.2 VALUE CHAIN ANALYSIS 31

5.2.1 R&D 32

5.2.2 MANUFACTURING 32

5.2.3 DISTRIBUTION & SALES 32

5.2.4 POST-SALES MONITORING 32

6 GLOBAL ALLERGIC RHINITIS MARKET BY TYPE

6.1 OVERVIEW 33

6.2 SEASONAL ALLERGIC RHINITIS 34

6.3 PERENNIAL ALLERGIC RHINITIS 34

6.4 OCCUPATIONAL ALLERGIC RHINITIS 35

7 GLOBAL ALLERGIC RHINITIS MARKET, BY TREATMENT

7.1 INTRODUCTION 36

7.2 ANTIHISTAMINES 37

7.3 CORTICOSTEROIDS 37

7.4 DECONGESTANTS 38

7.5 IMMUNOTHERAPY 38

7.6 INTRANASAL ANTICHOLINERGICS 38

7.7 OTHERS 39

8 GLOBAL ALLERGIC RHINITIS MARKET BY ROUTE OF ADMINISTRATION

8.1 OVERVIEW 40

8.2 NASAL 41

8.3 ORAL 41

8.4 OTHERS 42

9 GLOBAL ALLERGIC RHINITIS MARKET BY DISTRIBUTION CHANNEL

9.1 OVERVIEW 43

9.2 RETAIL PHARMACIES 44

9.3 HOSPITAL PHARMACIES 44

9.4 ONLINE STORES 45

10 GLOBAL ALLERGIC RHINITIS MARKET, BY REGION

10.1 INTRODUCTION 46

10.2 AMERICAS 48

10.2.1 NORTH AMERICA 50

10.2.1.1 US 52

10.2.1.2 CANADA 53

10.2.2 LATIN AMERICA 54

10.2.2.1 BRAZIL 56

10.2.2.2 ARGENTINA 58

10.2.2.3 COLUMBIA 59

10.2.2.4 CHILE 60

10.2.2.5 REST OF LATIN AMERICA 62

10.3 EUROPE 64

10.3.1.1 WESTERN EUROPE 66

10.3.1.2 GERMANY 68

10.3.1.3 FRANCE 69

10.3.1.4 UK 70

10.3.1.5 ITALY 72

10.3.1.6 SPAIN 73

10.3.1.7 REST OF WESTERN EUROPE 74

10.3.1.8 EASTERN EUROPE 76

10.4 ASIA-PACIFIC 78

10.4.1.1 JAPAN 80

10.4.1.2 CHINA 81

10.4.1.3 INDIA 83

10.4.1.4 AUSTRALIA 84

10.4.1.5 SOUTH KOREA 85

10.4.1.6 THAILAND 87

10.4.1.7 REST OF ASIA-PACIFIC 88

10.5 MIDDLE EAST & AFRICA 90

10.5.1.1 MIDDLE EAST 92

10.5.1.2 AFRICA 93

11 COMPETITIVE LANDSCAPE

11.1 INTRODUCTION 95

12 COMPANY PROFILES

12.1 ASTRAZENECA 97

12.1.1 COMPANY OVERVIEW 97

12.1.2 FINANCIAL OVERVIEW 97

12.1.3 PRODUCTS/SERVICES OFFERED 98

12.1.4 KEY DEVELOPMENTS 98

12.1.5 SWOT ANALYSIS 99

12.1.6 KEY STRATEGIES 99

12.2 BOEHRINGER INGELHEIM 100

12.2.1 COMPANY OVERVIEW 100

12.2.2 FINANCIAL OVERVIEW 100

12.2.3 PRODUCTS/SERVICES OFFERED 101

12.2.4 KEY DEVELOPMENTS 101

12.2.5 SWOT ANALYSIS 102

12.2.6 KEY STRATEGIES 102

12.3 MERCK & CO., INC. 103

12.3.1 COMPANY OVERVIEW 103

12.3.2 FINANCIAL OVERVIEW 103

12.3.3 PRODUCTS/SERVICES OFFERED 104

12.3.4 KEY DEVELOPMENTS 104

12.3.5 SWOT ANALYSIS 105

12.3.6 KEY STRATEGIES 105

12.4 GLAXOSMITHKLINE PLC 106

12.4.1 COMPANY OVERVIEW 106

12.4.2 FINANCIAL OVERVIEW 106

12.4.3 PRODUCTS/SERVICES OFFERED 107

12.4.4 KEY DEVELOPMENTS 107

12.4.5 SWOT ANALYSIS 108

12.4.6 KEY STRATEGIES 108

12.5 JOHNSON & JOHNSON SERVICES, INC. 109

12.5.1 COMPANY OVERVIEW 109

12.5.2 FINANCIAL OVERVIEW 109

12.5.3 PRODUCTS/SERVICES OFFERED 110

12.5.4 KEY DEVELOPMENTS 110

12.5.5 SWOT ANALYSIS 111

12.5.6 KEY STRATEGIES 111

12.6 BAYER AG 112

12.6.1 COMPANY OVERVIEWS 112

12.6.2 FINANCIAL OVERVIEW 112

12.6.3 PRODUCTS/SERVICES OFFERED 113

12.6.4 KEY DEVELOPMENTS 113

12.6.5 SWOT ANALYSIS 114

12.6.6 KEY STRATEGIES 114

12.7 ALK-ABELLΓ“ A/S 115

12.7.1 COMPANY OVERVIEW 115

12.7.2 FINANCIAL OVERVIEW 115

12.7.3 PRODUCTS/SERVICES OFFERED 116

12.7.4 KEY DEVELOPMENTS 116

12.7.5 SWOT ANALYSIS 117

12.7.6 KEY STRATEGIES 117

12.8 MEDA PHARMACEUTICALS 118

12.8.1 COMPANY OVERVIEW 118

12.8.2 FINANCIAL OVERVIEW 118

12.8.3 PRODUCTS/SERVICES OFFERED 119

12.8.4 KEY DEVELOPMENTS 119

12.8.5 SWOT ANALYSIS 120

12.8.6 KEY STRATEGIES 120

12.9 SANOFI 121

12.9.1 COMPANY OVERVIEW 121

12.9.2 FINANCIAL OVERVIEW 121

12.9.3 PRODUCTS/SERVICES OFFERED 122

12.9.4 KEY DEVELOPMENTS 122

12.9.5 SWOT ANALYSIS 123

12.9.6 KEY STRATEGIES 123

12.10 NOVARTIS AG 124

12.10.1 COMPANY OVERVIEW 124

12.10.2 FINANCIAL OVERVIEW 124

12.10.3 PRODUCTS/SERVICES OFFERED 125

12.10.4 KEY DEVELOPMENTS 125

12.10.5 SWOT ANALYSIS 126

12.10.6 KEY STRATEGIES 126

13 APPENDIX

13.1 REFERENCES 127

13.2 RELATED REPORTS 127

14 List of Tables

TABLE 1 LIST OF ASSUMPTIONS 17

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 21

TABLE 3 GLOBAL ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 34

TABLE 4 GLOBAL ALLERGIC RHINITIS MARKET FOR SEASONAL ALLERGIC RHINITIS, BY REGION, 2020–2027 (USD MILLION) 34

TABLE 5 GLOBAL ALLERGIC RHINITIS MARKET FOR PERENNIAL ALLERGIC RHINITIS, BY REGION, 2020–2027 (USD MILLION) 34

TABLE 6 GLOBAL ALLERGIC RHINITIS MARKET FOR OCCUPATIONAL ALLERGIC RHINITIS, BY REGION, 2020–2027 (USD MILLION) 35

TABLE 7 GLOBAL ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 37

TABLE 8 GLOBAL ALLERGIC RHINITIS MARKET FOR ANTIHISTAMINES, BY REGION, 2020–2027 (USD MILLION) 37

TABLE 9 GLOBAL ALLERGIC RHINITIS MARKET FOR CORTICOSTEROIDS, BY REGION, 2020–2027 (USD MILLION) 37

TABLE 10 GLOBAL ALLERGIC RHINITIS MARKET FOR DECONGESTANTS, BY REGION, 2020–2027 (USD MILLION) 38

TABLE 11 GLOBAL ALLERGIC RHINITIS MARKET FOR IMMUNOTHERAPY, BY REGION, 2020–2027 (USD MILLION) 38

TABLE 12 GLOBAL ALLERGIC RHINITIS MARKET FOR INTRANASAL ANTICHOLINERGICS, BY REGION, 2020–2027 (USD MILLION) 38

TABLE 13 GLOBAL ALLERGIC RHINITIS MARKET FOR OTHER TREATMENTS, BY REGION, 2020–2027 (USD MILLION) 39

TABLE 14 GLOBAL ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 41

TABLE 15 GLOBAL ALLERGIC RHINITIS MARKET FOR NASAL, BY REGION, 2020–2027 (USD MILLION) 41

TABLE 16 GLOBAL ALLERGIC RHINITIS MARKET FOR ORAL, BY REGION, 2020–2027 (USD MILLION) 41

TABLE 17 GLOBAL ALLERGIC RHINITIS MARKET FOR OTHER ROUTE OF ADMINISTRATION, BY REGION, 2020–2027 (USD MILLION) 42

TABLE 18 GLOBAL ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 44

TABLE 19 GLOBAL ALLERGIC RHINITIS MARKET FOR RETAIL PHARMACIES, BY REGION, 2020–2027 (USD MILLION) 44

TABLE 20 GLOBAL ALLERGIC RHINITIS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2020–2027 (USD MILLION) 44

TABLE 21 GLOBAL ALLERGIC RHINITIS MARKET FOR ONLINE STORES, BY REGION, 2020–2027 (USD MILLION) 45

TABLE 22 GLOBAL ALLERGIC RHINITIS MARKET, BY REGION, 2020–2027 (USD MILLION) 47

TABLE 23 AMERICAS: ALLERGIC RHINITIS MARKET, BY REGION, 2020–2027 (USD MILLION) 48

TABLE 24 AMERICAS: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 48

TABLE 25 AMERICAS: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 49

TABLE 26 AMERICAS: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 49

TABLE 27 AMERICAS: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 49

TABLE 28 NORTH AMERICA: ALLERGIC RHINITIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 50

TABLE 29 NORTH AMERICA: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 50

TABLE 30 NORTH AMERICA: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 51

TABLE 31 NORTH AMERICA: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 51

TABLE 32 NORTH AMERICA: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 51

TABLE 33 US: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 52

TABLE 34 US: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 52

TABLE 35 US: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 52

TABLE 36 US: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 53

TABLE 37 CANADA: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 53

TABLE 38 CANADA: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 53

TABLE 39 CANADA: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 54

TABLE 40 CANADA: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 54

TABLE 41 LATIN AMERICA: ALLERGIC RHINITIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 55

TABLE 42 LATIN AMERICA: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 55

TABLE 43 LATIN AMERICA: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 55

TABLE 44 LATIN AMERICA: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 56

TABLE 45 LATIN AMERICA: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 56

TABLE 46 BRAZIL: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 56

TABLE 47 BRAZIL: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 57

TABLE 48 BRAZIL: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 57

TABLE 49 BRAZIL: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 57

TABLE 50 ARGENTINA: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 58

TABLE 51 ARGENTINA: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 58

TABLE 52 ARGENTINA: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 58

TABLE 53 ARGENTINA: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 59

TABLE 54 COLUMBIA: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 59

TABLE 55 COLUMBIA: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 59

TABLE 56 COLUMBIA: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 60

TABLE 57 COLUMBIA: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 60

TABLE 58 CHILE: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 60

TABLE 59 CHILE: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 61

TABLE 60 CHILE: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 61

TABLE 61 CHILE: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 61

TABLE 62 REST OF LATIN AMERICA: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 62

TABLE 63 REST OF LATIN AMERICA: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 62

TABLE 64 REST OF LATIN AMERICA: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 62

TABLE 65 REST OF LATIN AMERICA: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 63

TABLE 66 EUROPE: ALLERGIC RHINITIS MARKET, BY REGION, 2020–2027 (USD MILLION) 64

TABLE 67 EUROPE: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 64

TABLE 68 EUROPE: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 65

TABLE 69 EUROPE: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 65

TABLE 70 EUROPE: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 65

TABLE 71 WESTERN EUROPE: ALLERGIC RHINITIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 66

TABLE 72 WESTERN EUROPE: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 66

TABLE 73 WESTERN EUROPE: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 67

TABLE 74 WESTERN EUROPE: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 67

TABLE 75 WESTERN EUROPE: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 67

TABLE 76 GERMANY: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 68

TABLE 77 GERMANY: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 68

TABLE 78 GERMANY: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 68

TABLE 79 GERMANY: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 69

TABLE 80 FRANCE: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 69

TABLE 81 FRANCE: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 69

TABLE 82 FRANCE: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 70

TABLE 83 FRANCE: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 70

TABLE 84 UK: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 70

TABLE 85 UK: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 71

TABLE 86 UK: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 71

TABLE 87 UK: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 71

TABLE 88 ITALY: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 72

TABLE 89 ITALY: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 72

TABLE 90 ITALY: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 72

TABLE 91 ITALY: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 73

TABLE 92 SPAIN: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 73

TABLE 93 SPAIN: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 73

TABLE 94 SPAIN: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 74

TABLE 95 SPAIN: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 74

TABLE 96 REST OF WESTERN EUROPE: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 74

TABLE 97 REST OF WESTERN EUROPE: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 75

TABLE 98 REST OF WESTERN EUROPE: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 75

TABLE 99 REST OF WESTERN EUROPE: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 75

TABLE 100 EASTERN EUROPE: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 76

TABLE 101 EASTERN EUROPE: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 76

TABLE 102 EASTERN EUROPE: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 76

TABLE 103 EASTERN EUROPE: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 77

TABLE 104 ASIA-PACIFIC: ALLERGIC RHINITIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 78

TABLE 105 SIA-PACIFIC: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 79

TABLE 106 ASIA-PACIFIC: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 79

TABLE 107 ASIA-PACIFIC: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 79

TABLE 108 ASIA-PACIFIC: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 80

TABLE 109 JAPAN: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 80

TABLE 110 JAPAN: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 80

TABLE 111 JAPAN: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 81

TABLE 112 JAPAN: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 81

TABLE 113 CHINA: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 81

TABLE 114 CHINA: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 82

TABLE 115 CHINA: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 82

TABLE 116 CHINA: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 82

TABLE 117 INDIA: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 83

TABLE 118 INDIA: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 83

TABLE 119 INDIA: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 83

TABLE 120 INDIA: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 84

TABLE 121 AUSTRALIA: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 84

TABLE 122 AUSTRALIA: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 84

TABLE 123 AUSTRALIA: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 85

TABLE 124 AUSTRALIA: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 85

TABLE 125 SOUTH KOREA: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 85

TABLE 126 SOUTH KOREA: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 86

TABLE 127 SOUTH KOREA: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 86

TABLE 128 SOUTH KOREA: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 86

TABLE 129 THAILAND: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 87

TABLE 130 THAILAND: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 87

TABLE 131 THAILAND: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 87

TABLE 132 THAILAND: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 88

TABLE 133 REST OF ASIA-PACIFIC: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 88

TABLE 134 REST OF ASIA-PACIFIC: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 88

TABLE 135 REST OF ASIA-PACIFIC: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 89

TABLE 136 REST OF ASIA-PACIFIC: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 89

TABLE 137 MIDDLE EAST & AFRICA: ALLERGIC RHINITIS MARKET, BY REGION, 2020–2027 (USD MILLION) 90

TABLE 138 MIDDLE EAST & AFRICA: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 90

TABLE 139 MIDDLE EAST & AFRICA: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 91

TABLE 140 MIDDLE EAST & AFRICA: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 91

TABLE 141 MIDDLE EAST & AFRICA: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 91

TABLE 142 MIDDLE EAST: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 92

TABLE 143 MIDDLE EAST: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 92

TABLE 144 MIDDLE EAST: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 92

TABLE 145 MIDDLE EAST: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 93

TABLE 146 AFRICA: ALLERGIC RHINITIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 93

TABLE 147 AFRICA: ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 93

TABLE 148 AFRICA: ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020–2027 (USD MILLION) 94

TABLE 149 AFRICA: ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 94

TABLE 150 ASTRAZENECA: PRODUCTS/SERVICES OFFERED 98

TABLE 151 ASTRAZENECA: KEY DEVELOPMENTS 98

TABLE 152 BOEHRINGER INGELHEIM: PRODUCTS/SERVICES OFFERED 101

TABLE 153 BOEHRINGER INGELHEIM: KEY DEVELOPMENTS 101

TABLE 154 MERCK & CO., INC.: PRODUCTS/SERVICES OFFERED 104

TABLE 155 MERCK & CO., INC: KEY DEVELOPMENTS 104

TABLE 156 GLAXOSMITHKLINE PLC: PRODUCTS/SERVICES OFFERED 107

TABLE 157 GLAXOSMITHKLINE PLC: KEY DEVELOPMENTS 107

TABLE 158 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS/SERVICES OFFERED 110

TABLE 159 BAYER AG: PRODUCTS/SERVICES OFFERED 113

TABLE 160 BAYER AG: KEY DEVELOPMENTS 113

TABLE 161 ALK-ABELLΓ“ A/S: PRODUCTS/SERVICES OFFERED 116

TABLE 162 ALK-ABELLΓ“ A/S: KEY DEVELOPMENTS 116

TABLE 163 MEDA PHARMACEUTICALS: PRODUCTS/SERVICES OFFERED 119

TABLE 164 MEDA PHARMACEUTICALS: KEY DEVELOPMENTS 119

TABLE 165 SANOFI: PRODUCTS/SERVICES OFFERED 122

TABLE 166 NOVARTIS AG: PRODUCTS/SERVICES OFFERED 125

15 List of Figures

FIGURE 1 MARKET SYNOPSIS 14

FIGURE 2 GLOBAL ALLERGIC RHINITIS MARKET: STRUCTURE 17

FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES 23

FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL ALLERGIC RHINITIS MARKET 26

FIGURE 5 PORTER’S FIVE FORCES ANALYSIS: GLOBAL ALLERGIC RHINITIS MARKET 29

FIGURE 6 VALUE CHAIN ANALYSIS OF THE GLOBAL ALLERGIC RHINITIS MARKET 31

FIGURE 7 GLOBAL ALLERGIC RHINITIS MARKET, BY TYPE, 2020 & 2027 (USD MILLION) 33

FIGURE 8 GLOBAL ALLERGIC RHINITIS MARKET, BY TREATMENT, 2020 & 2027 (USD MILLION) 36

FIGURE 9 GLOBAL ALLERGIC RHINITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020 & 2027 (USD MILLION) 40

FIGURE 10 GLOBAL ALLERGIC RHINITIS MARKET, BY DISTRIBUTION CHANNEL, 2020 & 2027 (USD MILLION) 43

FIGURE 11 GLOBAL ALLERGIC RHINITIS MARKET, BY REGION, 2020 & 2027 (USD MILLION) 47

FIGURE 12 AMERICAS: ALLERGIC RHINITIS MARKET SHARE, BY REGION 2020 (%) 48

FIGURE 13 NORTH AMERICA: ALLERGIC RHINITIS MARKET SHARE, BY COUNTRY 2020 (%) 50

FIGURE 14 LATIN AMERICA: ALLERGIC RHINITIS MARKET SHARE, BY COUNTRY 2020 (%) 54

FIGURE 15 EUROPE: ALLERGIC RHINITIS MARKET SHARE, BY REGION, 2020 (%) 64

FIGURE 16 WESTERN EUROPE: ALLERGIC RHINITIS MARKET SHARE, BY COUNTRY, 2020 (%) 66

FIGURE 17 ASIA-PACIFIC: ALLERGIC RHINITIS MARKET SHARE, BY COUNTRY, 2020 (%) 78

FIGURE 18 MIDDLE EAST & AFRICA: ALLERGIC RHINITIS MARKET SHARE, BY REGION, 2020 (%) 90

FIGURE 19 GLOBAL ALLERGIC RHINITIS MARKET, MARKET SHARE ANALYSIS 2020 (% SHARE) 95

FIGURE 20 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT 97

FIGURE 21 ASTRAZENECA: SWOT ANALYSIS 99

FIGURE 22 BOEHRINGER INGELHEIM: FINANCIAL OVERVIEW 100

FIGURE 23 BOEHRINGER INGELHEIM: SWOT ANALYSIS 102

FIGURE 24 MERCK & CO., INC.: FINANCIAL OVERVIEW SNAPSHOT 103

FIGURE 25 MERCK & CO., INC.: SWOT ANALYSIS 105

FIGURE 26 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT 106

FIGURE 27 GLAXOSMITHKLINE PLC.: SWOT ANALYSIS 108

FIGURE 28 JOHNSON & JOHNSON SERVICES, INC.: FINANCIAL OVERVIEW SNAPSHOT 109

FIGURE 29 JOHNSON & JOHNSON SERVICES, INC.: SWOT ANALYSIS 111

FIGURE 30 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT 112

FIGURE 31 BAYER AG: SWOT ANALYSIS 114

FIGURE 32 ALK-ABELLΓ“ A/S FINANCIAL OVERVIEW SNAPSHOT 115

FIGURE 33 ALK-ABELLΓ“ A/S: SWOT ANALYSIS 117

FIGURE 34 MEDA PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT 118

FIGURE 35 MEDA PHARMACEUTICALS: SWOT ANALYSIS 120

FIGURE 36 SANOFI: FINANCIAL OVERVIEW SNAPSHOT 121

FIGURE 37 SANOFI: SWOT ANALYSIS 123

FIGURE 38 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT 124

FIGURE 39 NOVARTIS AG: SWOT ANALYSIS 126

Allergic Rhinitis Market

The allergic rhinitis market is projected to be worth USD 16,012.57 million by 2027, registering a CAGR of 3.30 % during the forecast period.

Segmentation

By Type Seasonal Allergic Rhinitis Perennial Allergic Rhinitis Occupational Allergic Rhinitis
Treatment Antihistamines Corticosteroids Immunotherapy Decongestants And Others
Route of Administration Oral Nasal And Others

Key Players

  • AstraZeneca
  • GlaxoSmithKline plc
  • Johnson & Johnson Services
  • Inc
  • Bayer AG
  • Sanofi
  • Boehringer Ingelheim
  • Merck & Co.
  • ALK-AbellΓ³ A/S
  • Novartis AG
  • Meda Pharmaceuticals

Drivers

  • increasing prevalence of allergic rhinitis
  • increasing government initiatives to spread awareness about allergic diseases.
Speak to Analyst Request a Free Sample

Allergic Rhinitis Market overview


The allergic rhinitis market is currently growing at a CAGR of 3.30%. The market is expected to be worth the USD 16,012.57 Million by 2027. Growth is expected to be strong inallergic rhinitis market until at least the end of 2027. 
 
Allergic rhinitis is becoming more of a problem worldwide. Various governments around the world are investing heavily in educational campaigns regarding various allergies and the many ways that allergic rhinitis medicines can help alleviate these. 
 
COVID-19 analysis
 
COVID-19 became a global nuisance in the Spring of 2020. At first, governments thought that this virus was nothing more than a stronger version of the flu. However, many people reported long-term side effects months after having recovered from the virus. Some of these conditions included diabetes and strokes. What complicated matters further was the fact that the antibodies only lasted for a few months. Therefore, those who recovered could get it again.
 
Governments around the world responded with mandatory lockdowns and quarantines. This adversely affected the allergic rhinitis market. Many companies found it difficult to source the raw materials for these drugs. This pushed production costs up. These companies were forced to pass these costs onto the end consumer in the form of higher prices.
Global Allergic Rhinitis Market Share, by Treatment, 2018 (%)  Allergic Rhinitis Market
Source: MRFR Analysis

Market dynamics

Drivers


Climate change has meant that more and more people around the world are suffering from seasonal or long-term allergies. Since these allergies can be severe, governments around the world have been launching marketing and educational programs and campaigns that are designed to warn and inform people about allergies. These campaigns are also designed to promote allergic rhinitis drugs as much as possible.
 
Many private and national healthcare providers are responding by covering allergic rhinitis drugs and treatments. This phenomenon is expected to be a major driver of growth until at least the end of 2027. 
 
According to the European Academy of Allergy and Clinical Immunology (EAACI), approximately 150 million people in Europe suffer from chronic allergies. About two-thirds of those are suffering from allergic rhinitis.


  • Opportunities


Massive government educational programs about allergic rhinitis are expected to create many new opportunities for the allergic rhinitis drugs market. This is especially true because companies are investing heavily in research and development. This is allowing them to create a new generation of over-the-counter and prescription allergic rhinitis drugs that can sell for very high prices. These new-generation drugs are far more effective at relieving the symptoms of allergic rhinitis for longer. 


  • Restraints


One factor that could potentially hamper growth in the allergic rhinitis market is the many side effects. Though rare, some of these side effects can be dangerous and even deadly!


  • Challenges


One major challenge that companies in the allergic rhinitis market face are the issue of keeping production costs down. This will make these drugs more affordable and result in more sales. COVID-19 and its aftermath have only exacerbated this challenge. 


  • Cumulative growth analysis


The CAGR of this allergic rhinitis market is expected to be 3.30% by the end of 2027. The allergic rhinitis drugs market is expected to be worth USD 16,012.57 Million by the end of 2025.
 
Technology analysis
 
Merck & Co has been at the forefront in terms of research and development in the allergic rhinitis market. The results have paid off. One new generation of allergy drugs is Asmanex. This is a prescription medicine. It’s an aerosol corticosteroid that’s taken nasally. Asmanex is a strong drug that can relieve many allergy symptoms for longer. 
Global Allergic Rhinitis Market Share, 2018 (%)  Allergic Rhinitis Market
Source: MRFR Analysis
Segment overview
 
By type

The allergic rhinitis market can be classified into the following categories based on type:
● Seasonal allergic rhinitis
● Perennial allergic rhinitis
● Occupational allergic rhinitis.
 
By treatment
 
There are many types of treatments for allergic rhinitis. These are antihistamines, corticosteroids, decongestants, immunotherapy—intranasal anticholinergics, etc.
 
By administration
 
There are three primary ways that allergic rhinitis industry can be administered:
● Nasal
● Oral
● Others
 
By distribution
 
Retail pharmacies, hospital pharmacies, and online stores are the primary distribution channels for allergic rhinitis drugs.
 
By region
 
The global allergic rhinitis market is separated into the following regions:
● The Americas
● Europe
● Asia-Pacific
● The Middle East and North Africa
 
Regional analysis
 
America holds the largest market share for the allergic rhinitis market by sheer numbers and percentages. One of the main reasons for this is that the vast majority of the pharmaceutical companies that make allergic rhinitis drugs are in America. 
 
These companies have been strengthening their position in America and in various other regions of the world by acquiring key companies. This move is also helping them enter into new markets around the world. They’ve also been using strategic acquisitions to expand the number and type of allergic rhinitis drugs that they sell. 
 
What’s driving growth in this country is the increasing prevalence of allergies and related breathing problems. According to the National Center for Biotechnology Information, approximately 15% of the total population suffers from allergic rhinitis. This is diagnosed by a doctor. These patients are often prescribed powerful prescription meds. 
 
The European Union holds the second largest market share in the world. What’s driving growth and accounting for a high market share in this region is the fact that many hospitals offer the new generation of powerful allergic rhinitis drugs to their patients. People suffering from allergies in the European Union can also access a new generation of powerful allergic rhinitis drugs over-the-counter.
 
The Global Allergy and Asthma European Network have taken great measures to ensure that European pharmaceutical companies continue to do the research and development that leads to even more powerful and effective drugs in the future. This network has also ensured that this research is carried out by and meets high standards.
 
The Asia-Pacific region is expected to have the highest CAGR of all world regions during this projected time period. India and China account for the vast majority of new allergic rhinitis cases. What is accounting for this is the fact that these nations are heavily polluted. The fact that more and more people are smoking in these two countries also doesn’t help. 
 
Many people are also exposed to polluting particles both in their homes and workplaces. The CAGR for the Asia-Pacific region is expected to be higher than the overall global CAGR. The CAGR for the Asia-Pacific region is expected to be 3.65% from the years between 2019 and 2025.
 
The allergic rhinitis market is expected to experience modest CAGR in the Middle East and North Africa regions from the years spanning 2019 to 2025. Saudi Arabia and the seven city nations in the United Arab Emirates (UAE) will account for most of the growth in this region. These nations have advanced healthcare systems. They can also afford to spend much more on ensuring that these drugs end up in hospitals and health clinics. Finally, people are becoming richer in these nations and can afford to spend more on these drugs. 
 
Competitive landscape
 
The global allergic rhinitis market remains highly fragmented. This makes it very competitive. Companies are using three strategies to remain profitable. They are investing heavily in research and development. They are also entering into strategic partnerships and acquiring key companies. The objective is to solidify existing market positions and to enter into new markets on a strong foot.
 
Merck & Co is a key company. It has prospered by investing heavily in research and development. This has allowed it to bring to market a new generation of more powerful and effective allergic rhinitis drugs.
 
List of Companies
 
● AstraZeneca - USA
● GlaxoSmithKline plc - United Kingdom
● Johnson & Johnson Services Inc., - the USA
● Bayer AG - Germany
● Sanofi - France
● Boehringer Ingleheim - Germany
● Merck & Co - USA
● ALK-Abello A/S - Denmark
● Novartis AG- Switzerland
● Meda Pharmaceuticals - Sweden
 
Recent developments
 
● Keytruda, when combined with LENVIA, helped more patients stay in remission from cancer
● The European Union approves Keytruda
● Merck gets priority approval from the FDA for Belzutifan
● Merck presents data from various HIV treatment programs
● The FDA accepts and reviews the application for Gefapixant
 
Report overview
 
The CAGR for the global allergic rhinitis market is 3.10%. The prevalence of allergies has been increasing throughout the world. This is combined with government efforts around the world to promote the usage of these drugs. The Asia-Pacific region had the highest regional CAGR of 3.65%. India and China are developing rapidly. The pollution - both indoors and outdoors - is increasing dramatically and rapidly in these nations. Added to this is the fact that more and more people are smoking in these two nations.



Report Scope:
Report Attribute/Metric Details
  Market Size   USD 16,012.57 Million 2027
  CAGR   3.30% (2021-2027)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Treatment, Route of Administration and Distribution Channel
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   AstraZeneca, GlaxoSmithKline plc, Johnson & Johnson Services, Inc, Bayer AG, Sanofi, Boehringer Ingelheim, Merck & Co., ALK-AbellΓ³ A/S, Novartis AG, Meda Pharmaceuticals
  Key Market Opportunities   growing healthcare expenditure and expansion of the private healthcare system
  Key Market Drivers

  • increasing prevalence of allergic rhinitis
  • increasing government initiatives to spread awareness about allergic diseases


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Allergic Rhinitis Market is predicted to touch USD 15064.12 million by 2027.

    Allergic Rhinitis Market is projected to grow at a 3.10% CAGR between 2021-2027.

    Americas is projected to have a major share in the Allergic Rhinitis Market.

    Increasing government initiatives and rising prevalence of Allergic Rhinitis are boosting market growth.

    Side effects of medications may impede market growth.